Gestational Glucose Intolerance and Risk of Future Diabetes
Diabetes Care · 2023
DOI: 10.2337/dc22-1390 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, 2023. Verfasst von Daryl J Selen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Unit, Massachusetts General Hospital, Boston, MA. Hauptthemen laut MEDLINE: Glucose Intolerance, Diabetes, Gestational. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Massachusetts General Hospital, National Institute of Diabetes and Digestive and Kidney Diseases.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE Pregnant individuals are universally screened for gestational diabetes mellitus (GDM). Gestational glucose intolerance (GGI) (an abnormal initial GDM screening test without a GDM diagnosis) is not a recognized diabetes risk factor. We tested for an association between GGI and diabetes after pregnancy. RESEARCH DESIGN AND METHODS We conducted a retrospective cohort study of individuals followed for prenatal and primary care. We defined GGI as an abnormal screening glucose-loading test result at ≥24 weeks’ gestation with an oral glucose tolerance test (OGTT) that did not meet GDM criteria. The primary outcome was incident diabetes. We used Cox proportional hazards models with time-varying exposures and covariates to compare incident diabetes risk in individuals with GGI and normal glucose tolerance. RESULTS Among 16,836 individuals, there were 20,359 pregnancies with normal glucose tolerance, 2,943 with GGI, and 909 with GDM. Over a median of 8.4 years of follow-up, 428 individuals developed diabetes. Individuals with GGI had increased diabetes risk compared to those with normal glucose tolerance in pregnancy (adjusted hazard ratio [aHR] 2.01 [95% CI 1.54–2.62], P < 0.001). Diabetes risk increased with the number of abnormal OGTT values (zero, aHR 1.54 [1.09–2.16], P = 0.01; one, aHR 2.97 [2.07–4.27], P < 0.001; GDM, aHR 8.26 [6.49–10.51], P < 0.001 for each compared with normal glucose tolerance). The fraction of cases of diabetes 10 years after delivery attributable to GGI and GDM was 8.5% and 28.1%, respectively. CONCLUSIONS GGI confers an increased risk of future diabetes. Routinely available clinical data identify an unrecognized group who may benefit from enhanced diabetes screening and prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Diabetes Unit, Massachusetts General Hospital, Boston, MA.
- Department of Medicine, Massachusetts General Hospital, Boston, MA.
- Harvard Medical School, Boston, MA.
- Division of Endocrinology, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, RI.
- Biostatistics Center, Division of Clinical Research, Massachusetts General Hospital, Boston, MA.
- Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA.
ORCID-Profile: Camille E Powe
Förderung
- NIDDK NIH HHS
- Massachusetts General Hospital
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Selen, D. J., Thaweethai, T., Schulte, C. C. M., Hsu, S., He, W., James, K., Kaimal, A., Meigs, J. B., & Powe, C. E. (2023). Gestational Glucose Intolerance and Risk of Future Diabetes. Diabetes Care. https://doi.org/10.2337/dc22-1390
Vancouver
Selen DJ, Thaweethai T, Schulte CCM, Hsu S, He W, James K, et al. Gestational Glucose Intolerance and Risk of Future Diabetes. Diabetes Care. 2023. doi:10.2337/dc22-1390
BibTeX
@article{Selen2023,
author = {Selen, Daryl J and Thaweethai, Tanayott and Schulte, Carolin C M and Hsu, Sarah and He, Wei and James, Kaitlyn and Kaimal, Anjali and Meigs, James B and Powe, Camille E},
title = {Gestational Glucose Intolerance and Risk of Future Diabetes},
journal = {Diabetes Care},
year = {2023},
doi = {10.2337/dc22-1390}
}
EUVIMED